Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma

John F Tarlton, D I Easty

In Europe and North America, retinoblastoma has a reported incidence ranging from 1 in 14 000 to 1 in 36 000 live births and is the most common ocular malignancy affecting children and infants. Early diagnosis allows the application of a number of therapies directed at localised disease, including external beam and plaque radiotherapy, cryotherapy, and photocoagulation, although the principal treatment accounting for the high cure rate of around 90% is enucleation, which is still carried out in over half of all cases. The justification for such radical therapy is the poor prognosis once the tumour escapes the eye, and the high mortality from metastases.

In the developing countries of Africa and Asia the picture is different. The higher reported incidence in many areas, coupled with a lower incidence of ocular malignant melanoma in particular racial groups results in retinoblastoma being the commonest ocular tumour in all age groups. Moreover, late diagnosis and treatment lead to a correspondingly high rate of mortality due to metastatic spread, approaching 100% in some areas.

Therefore the inability to deal effectively with metastatic retinoblastoma results in a high mortality in areas where medical care is limited and the extensive use of prophylactic enucleation in developed countries. Despite the efficacy of current therapeutic intervention, there remains a need for further investigation into improvements in treatment of metastatic disease.

Recent advances in the understanding of the cancer process are due largely to the advent of molecular genetics and the use of monoclonal antibodies, and perhaps the greatest contribution of such techniques has been in studies of retinoblastoma. The occasional association of the familial predisposition to retinoblastoma with a visible chromosome deletion at 13q14, and the linkage to the gene coding for esterase-D, confirmed the genetic basis for this disease. Epidemiological evidence led Knudson to formulate the 'two hit' hypothesis for the tumorigenesis of retinoblastoma, postulating that both copies of the viable gene must be inactivated by two independent mutational events (or 'hits'). An individual with the familial predisposition has inherited one inactive gene, such that only one subsequent mutational event is necessary, during the susceptible stage of embryonic development, to cause a retinoblast to become malignant. Retinoblastoma was the first cancer to be identified with a tumour suppressor gene, or anti-oncogene, to have this gene, RB1, located and cloned, and its protein product, p110, isolated. The inheritance is autosomally dominant in individuals with a single germline mutation due to the high probability of a second 'hit' inactivating the single remaining viable copy of the gene in one or more of the vulnerable retinoblasts. This malignancy is recessive at the genetic level, as indicated by the frequent loss of heterozygosity in tumour cells and reversal of the malignant phenotype in tumour derived cell lines fused with RB1 competent cells. Reversal of malignancy has also been reported in cell lines transfected with functional BR1 gene constructs. Recently, however, these results have been challenged by other researchers who have found incomplete reversal of malignancy in retinoblastoma cell lines, although such effects may be artefacts resulting from additional genetic changes having occurred in cells adapting to tissue culture environments. The importance of RB1 in malignant transformation has also been demonstrated by inactivating its product by association with virus proteins such as adenovirus E1A, SV40 large T antigen and papillomavirus E7 oncoprotein, both by transfection and transgenic manipulations. Furthermore, this gene has been implicated in the progression of other cancers, such as colon and breast carcinomas, and hence its significance as a tumour suppressor extends beyond its role in the tumorigenesis of retinoblastoma.

Perhaps the greatest recent clinical advance to emerge from theoretical studies of retinoblastoma, is in the field of prenatal and perinatal screening and genetic counselling. The predisposing gene for retinoblastoma may be identified using DNA probes recognising restriction fragment length polymorphisms (RFLP, variable length fragments of DNA prepared by sequence dependent endonuclease activity) on Southern blot analyses of genomic DNA. This enables predisposed individuals to be identified in utero, as well as recognising carriers of the aberrant retinoblastoma gene in cases of incomplete penetrance.

Monoclonal antibodies provide highly specific molecular recognition that can characterise and selectively localise tumour cells. To date their greatest contribution has been in elucidating the cellular origin of tumours, by equating immunohistochemical profiles in neoplastic cells with those of defined cell types in their tissue of origin. Although antibodies are highly specific for their molecular markers, the apparent lack of antigens expressed uniquely by cancer cells has limited their diagnostic and therapeutic applications. By identifying the inadequacies of monoclonal antibodies, researchers are now devising means of optimising their use in the clinical situation, and recent advances in recombinant technology may help in overcoming many of their limitations.

Immunohistochemistry in defining cellular origin

The immunochemical reactivity of tumour samples and cell lines such as Y79 and WERI RB1 has been investigated using monoclonal antibodies which recognise markers associated with particular tissues and cell types. Such markers include retinal S antigen, inter-retinoid binding protein, opsins, and rhodopsin, all associated with photoreceptors; S100 and glial fibrillary acidic protein associated with glial cells; neuron specific enolase, tetanus toxin and
dopamine B hydroxylase, neurofilaments and synaptophysin are all characteristic of neuronal cells. From the presence of these markers, a tumour origin from photoreceptors, glial, or neuronal cells has been postulated, as well as from a primitive common progenitor cell.

An alternative approach has been to equate antigenic heterogeneity with cell types, and therefore the differentiation potential of their common progenitor, the cell of origin of the tumour. By correlating with the known cell lineage of developing embryonic retinal cells, this allows definition of the tumour stem cell in terms of normal retinal progenitors (Figs 1, 2, and 3). Results from this work, and the weight of evidence from other studies, indicate that the tumour probably arises from a primitive multipotent neuro-epithelial cell of early embryogenesis, and present in declining numbers into later stages of development. This would offer an ever shrinking target for Knudson's second 'hit', and account for the reduction in incidence with advancing age. Furthermore, if the second 'hit' is sustained when partial differentiation has already occurred, this may result in the less malignant form of the disease described as retinocytoma or retinoma.

The use of histological sections of tumour tissue and established retinoblastoma cell lines present some difficulties in interpretation. The tumour may have incorporated non-neoplastic cells such as normal retinal and reactive glial cells, and cell lines of retinoblastoma are thought to be modulated extensively in tissue culture. In addition, cell lines may not possess the full differentiation capacity of the tumour stem cell, and are therefore not necessarily representative.

**Immunocytochemistry in differential diagnosis and prognosis**

There are a number of conditions which simulate retinoblastoma in presentation, including Coats' disease, persistent hyperplastic primary vitreous, and toxocariasis. Up to 30% of eyes enucleated for suspected retinoblastoma have been misdiagnosed, and yet delayed treatment of the tumour resulting from ambiguous presentation may prove fatal. Accurate differential diagnosis is therefore essential if appro-

**Figure 1** Immunohistochemical reactivity profiles of retinoblastoma, adult, and fetal retina with respect to seven differentially marking monoclonal antibodies. Tumour may be distinguished from normal retinal cell types using a panel of antibodies. NF = nerve fibre, GC = ganglion cell, IP = inner plexiform, IN = inner nuclear, OP = outer plexiform, ON = outer nuclear, PR = photoreceptor, C = choroid.

**Figure 2** Immunohistochemical reactivity of retinoblastoma compared with adult and fetal retina, with respect to seven monoclonal antibodies. Positive retinoblastoma and adult retina reactivity denoted as +; reactivity of 13 and 16 week retina is indicated by the number attributed to each monoclonal antibody. The tumour cell of origin is able to generate cell types expressing markers characteristic of both inner and outer retina. A stem cell with comparable differentiation potential is the neuroepithelial cell of 8 weeks' gestation.

**Figure 3A** Retinoblastoma reaction with anti-NCAM, UJ13A; very strong cell membrane expression of this adhesion molecule (original magnification x480).

**Figure 3B** Retinoblastoma reaction with anti-L1 adhesion molecule, UJ127.11; strong cell membrane expression (original magnification x120).
private treatment is to be given, and immunocytochemical procedures have a role to play in this.

The choice of therapy also rests upon an appraisal of the primary tumour progression, based on the Reese-Elsworth classification,¹⁴¹⁵ and the presence or degree of metastatic dissemination. The use of monoclonal antibodies in identifying retinoblastoma cells, particularly at distal sites, is proving to be important in prognostic evaluation.

Ocular toxocariasis results from infestation of the eye with the larval stage of the dog ascarid *Toxocara canis*. Immunological assays using the serum of affected individuals are diagnostic for this disease in most cases,¹⁶¹⁷ although this cannot be used to positively exclude retinoblastoma.

The reliability of diagnostic aqueous humour cytological assays following anterior chamber paracentesis, may be enhanced by the use of monoclonal antibodies. This may be important in confirmation of Coats’ disease¹⁸ and in distinguishing between diffuse infiltrating retinoblastoma, requiring immediate enucleation, and inflammatory hypopyon associated with uveitis, where non-invasive examination by ultrasound or computed tomography may prove inconclusive.⁴⁴⁻⁴⁶ Similarly, the cytological analysis of fine needle biopsies may be improved by the use of immunocytochemical techniques, although possible tumour seeding in this procedure may limit its use.¹⁹⁻²⁰

The two main risk factors influencing prognosis that may be identified in enucleated eyes are optic nerve involvement, particularly at the resection margin, and trans-scleral extension.⁴⁴⁻⁴⁶ Other factors which are generally indicative of terminal disease are central nervous system (CNS) involvement and bone marrow metastasis.⁴⁷ Generally such features can be identified by conventional histological procedures, although their reliability and accuracy may be enhanced by immunohistochemical staining.

Immunohistological techniques may be used to detect small numbers of invasive retinoblastoma cells within the sclera, because they uniformly express determinants not associated with choroidal-scleral tissue or inflammatory cells. An example of this is neural cell adhesion molecule (NCAM), for which there is a number of specific monoclonal antibodies, including UJ13A⁴⁸⁻⁵⁰ and ERIC-1.⁵¹⁻⁵³ Differentiation of optic nerve infiltration by retinoblastoma cells is more problematic, as many of the determinants which may potentially distinguish the tumour cells from surrounding neuronal tissue, such as anti-Thy 1,⁵⁴ or anti-opsin,⁵⁵ are those which are not uniformly or consistently expressed by the tumour cells. This may be circumvented by applying staining to a sufficient number of invasive cells such that the subpopulation expressing the antigen in question is represented in the sample, or by using a panel of monoclonal antibodies on separate histological sections.⁵⁶⁻⁵⁸ We have demonstrated that, by using such a panel of antibodies, it is possible to distinguish the tumour cells from individual cell types of adult and fetal retina by their immunoreactivities alone (Fig 1). These procedures require substantial tumour infiltration in order to provide sufficient tissue for analysis, in which case conventional techniques would probably prove adequate.

These and many other problems associated with the use of monoclonal antibodies would be resolved were a retinoblastoma specific antigen to be identified. Such a marker is proving elusive, not only in retinoblastoma but in other cancers, despite much investigation and many failed candidates. Researchers in our laboratories are presently engaged in a study isolating cell surface glycoproteins by lectin affinity, and separation by sodium dodecyl sulphate polyacrylamide gel electrophoresis in an effort to identify membrane components unique to retinoblastoma.

Cerebrospinal fluid (CSF) cytology, without the assistance of immunohistochemistry, has been used in assessing CNS involvement,⁵⁹ although procedures may prove equivocal when trying to identify cells away from their original site, where normal histological clues are missing. Interpretation of these assays may again be helped by the use of monoclonal antibody panels, as has been utilised in identifying medulloblastoma and neuroblastoma cells in the CSF of

---

**Figure 3C**  Sixteen week fetal retina reaction with anti-NCAM; very strong expression throughout all layers of the retina (original magnification x165).

**Figure 3D**  Sixteen week fetal retina reaction with anti-L1; inner retina reacts very strongly, but only weak expression in the outer retina (original magnification x65). NF = nerve fibre, GC = ganglion cell, IP = inner plexiform, ONB = outer neuroblastic layer, RPE = retinal pigment epithelium.
patients with suspected neoplastic invasion of the meninges.\textsuperscript{38} Haematogenous metastasis of retinoblastoma to bone marrow is generally indicative of terminal disease, as examples of successful treatment have made use of aggressive radiotherapy and chemotherapy combined with autologous transplant of purged marrow.\textsuperscript{37} It is important to identify accurately metastatic retinoblastoma cells in bone marrow in order to determine the most appropriate therapy, to monitor the course of the disease during remission or relapse, and to ensure that autologous transplant samples are free of tumour cells. Retinoblastoma cells individually resemble some monoclonal components of normal bone marrow, making definitive identification of tumour cells difficult. Immunochemistry has been used in a number of studies to identify accurately neuroblastoma cells in bone marrow aspirates and trephine biopsies,\textsuperscript{36,37,39,40} and such techniques are equally applicable to the recognition of metastatic retinoblastoma cells.

**Immunoscintigraphy in tumour imaging**

Perhaps the greatest use of antibody localisation in tumour diagnosis is in the field of immunoscintigraphy. For this procedure \(\gamma\) emitters such as iodine-125, iodine-131, technetium-99m, or iodium-111 are linked to monoclonal antibodies of maximal tumour selectivity, such as anti-carcinoembryonic antigen. The reagents are administered systemically, and the image is read on a gammacamera. Early efforts at immunoscintigraphic imaging compared poorly with other non-invasive scanning techniques such as \(x\) ray computed tomography, ultrasonography, and magnetic resonance imaging. Recent advances in \(\gamma\) image enhancement, such as single photon emission computed tomography and computer subtraction of a second image obtained using non-antigenic protein interactions, have led to improved sensitivity and image clarity of immunoscintigraphy.\textsuperscript{46} This has allowed accurate and reliable imaging of such malignancies as colorectal carcinoma (73\% predictive),\textsuperscript{47} ovarian carcinoma (67\% predictive),\textsuperscript{48} and thyroid carcinoma,\textsuperscript{49} and favourable comparisons with computed tomography and ultrasound.\textsuperscript{50,51}

Primary ocular retinoblastoma is usually diagnosed as a result of clinical examination alone and the extent of the tumour is evaluated in a similar way. Differential diagnosis from simulating lesions often requires the use of ancillary tests, and orbital or optic nerve extension cannot be assessed readily by superficial examination. Typical characteristics of advanced ocular retinoblastoma are tumour necrosis and calcification, which may be identified by computed tomography scanning and ultrasonography,\textsuperscript{46,52} and local exten-
sions may be visualised further by magnetic resonance imaging.\textsuperscript{47} The success of such techniques in diagnosing and evaluating primary retinoblastoma has limited the application of immunoscintigraphy in imaging localised disease. There is potential for this technique, though, in evaluating metastatic progression where alternative scanning procedures may prove inadequate. Presently the technique is not considered reliable for secondary lesions of less than 1 cm\(^2\), and therefore micrometastases, which contribute greatly to the progression of this disease, may escape detection. On the other hand, non-specific localisations, which are a major limitation in therapeutic targeting, may in many cases be predicted and discounted.

It is possible that improvements in tumour localisation, with production of monoclonal antibodies of greater specificity, along with advances in imaging techniques, may lead to the application of immunoscintigraphy in the evaluation of metastatic retinoblastoma, although it is unlikely that this technique will ever have the sensitivity needed for identifying microscopic lesions.\textsuperscript{48}

**Therapeutic uses of monoclonal antibodies**

A major factor inhibiting the use of new treatments in retinoblastoma and other neoplasms is the belief that antibody targeting, is the perceived high success rate with current treatments.

The survival rate of around 90\% of cases in developed countries is achieved at the cost of the loss of one or both eyes in over 50\% of cases and impairment in visual acuity in still more. Although maintenance of sight is an important consideration, survival is the first priority and therapy which does not guarantee comparable life expectancy with established treatment is justifiably viewed with some caution, presenting an ethical dilemma in the relative priorities of mortality and morbidity.\textsuperscript{50} This is particularly the case with speculative or experimental therapy, such as immunotherapies, when these have not been validated for cancers in which conventional treatment is less successful. In addition to enucleation, successful therapy relies heavily on techniques such as external beam and episcleral plaque irradiation, cryotherapy, and phacoemulsification, which are generally limited in their applications to localised disease.\textsuperscript{51,52}

Disseminated retinoblastoma responds poorly to systemic therapy, and this greatly contributes to the high mortality associated with this disease once it is allowed to spread.\textsuperscript{53} The use of chemotherapy has not delivered significant improvements in patient survival, and has now been abandoned in some centres.\textsuperscript{54} Cyclophosphamide is the most popular drug for single agent therapy, but increasingly multiagent regimens are being applied, such as cyclophosphamide, vincristine, and Adriamycin (doxorubicin).\textsuperscript{55} Intrathecal methotrexate has also been applied when CNS involvement is indicated.\textsuperscript{56,57} The aim of chemotherapy is selective elimination of tumour cells while limiting damage to normal tissues, requiring an adequate differential response between tumour and normal tissue. This has not been achieved in the case of metastatic retinoblastoma, for which prohibitively toxic doses are required to eliminate the tumour cells.\textsuperscript{58} It has long been recognised that antibodies may provide this missing selectivity\textsuperscript{59} and their use in therapeutic cancer targeting remains a principal goal for oncologists. The promise of specific antibody directed cancer therapy has proved elusive,\textsuperscript{70,71} although the obstacles which must be overcome are now more clearly defined. These include a lack of tumour specific target antigens,\textsuperscript{71,72} low antigen densities,\textsuperscript{73} heterogeneity and antigenic modulation in tumours (leading to treatment resistant clones),\textsuperscript{74,75} low absolute immunoconjugate localisations,\textsuperscript{76,77} rapid clearance of conjugates from circulation and tissues,\textsuperscript{78,79} poor penetration of high molecular weight reagents,\textsuperscript{80} non-specific retentions and interactions of targetting and effector components, and the patient's own immune reaction to foreign immunoglobulin (human anti-mouse antibody or HAMA response).\textsuperscript{81,82} Furthermore, the number of effector units which may be linked to each carrier antibody limits the therapeutic targeting and raises the toxicity required from each conjugate.\textsuperscript{83}

Targeting of chemotherapeutic drugs currently in use, such as methotrexate, has shown enhanced specificity for cancer cells.\textsuperscript{84} Nevertheless, the low doses reaching the tumour demand a greater toxicity than is provided by such reagents. Highly potent plant toxins, such as ricin and abrin, have been used successfully in monoclonal antibody directed killing of tumour cells in experimental models of malignancies,\textsuperscript{85,86} including retinoblastoma,\textsuperscript{87} but non-specific toxicity has precluded their use in systemic human therapy. The targeting of plant toxins, though, has found a practical use in the purging of metastatic cancer cells from bone marrow samples before autologous transplant.\textsuperscript{88}

Purging of bone marrow samples may also be carried out by mechanical separation, using magnetic microsphere conjugates. This technique has been successfully applied in
patients with haematogenous metastasis of retinoblastoma, using a cocktail of six monoclonal antibodies raised against neuroblastoma.  

Therapeutic use of antibody guided radionuclides is a natural extension of radioimmunotherapy, and application of radiolabelled monoclonal antibodies has produced efficacious results in xenograft animal models of human malignancy.  

Systemic immunoradiotherapy of cancer in human patients has demonstrated consistently disappointing responses, due mainly to extremely low localisation of reagents, of the order of 0.001%–0.005% of injected dose per gram of tumour. Furthermore, non-specific sequestration within untargeted viscera and retention of residues in the liver and kidneys have limited the tumour selectivity of intravenously applied reagents. For these reasons there has been interest in the direct application of antibody reagents to body cavities to treat compartmentalised tumours. Intraperitoneal instillation has been used to target ovarian carcinoma, and both neoplastic meningitis and CNS leukaemia have been treated with intrathecal administration of iodine-131 labelled monoclonal antibody with promising results.  

Intrathecal conjugate administration may also be applied to the treatment of CNS extension of retinoblastoma, presently associated with terminal disease, and results may be expected to be comparable with other secondary neoplastic meningial disease.  

Intraocular retinoblastoma is perhaps the most compartmentalised of all tumours, and as such may be amenable to the direct application of targeting monoclonal antibodies, particularly as the blood-retinal barrier may hinder systemic treatment is such cases. The lack of an adequate model of intraocular retinoblastoma has hampered investigation of such experimental therapies, but the recent development of a transgenic murine model may permit evaluation in primary disease.

**Figure 4** Antibody-directed enzyme prodrug therapy (ADEPT). Pretargeted antibody-enzyme conjugate is potentiayed by application of prodrug, and generates active drug at the tumour site.

**Figure 5** Bispecific monoclonal antibody in tumour targeting.
Both enzymes need to be present simultaneously in order to drive a two-stage reaction activating a prodrug, or pretoxin, which is applied when the tumour/tissue ratio is optimal. In this way enhanced selectivity of targeting may be achieved by combining the specificities of both delivery monoclonal antibodies (Fig 6). As there are less stringent demands on individual antigen specificities, those expressed consistently, and at a higher density, may be selected as targets.52

The human anti-mouse antibody reaction presents severe limitations on repeat applications of therapy which utilises murine monoclonal antibodies, causing the reagents to be cleared so rapidly as to prevent adequate access to the target cells.79 80 81 Systemic immunosuppression, using agents such as cyclosporin A, or induction of specific tolerance of the monoclonal antibody by coupling with polyethylene glycol, may be helpful in reducing this reaction.79 Alternative strategies for minimising the impact of the human anti-mouse antibody reaction are to reduce or eliminate the murine component of the antibodies. This may be achieved by using human monoclonals, produced by hybridoma technology, or by transforming human peripheral B lymphocytes with Epstein-Barr virus. Practical and ethical problems preclude routine immunisations of human subjects, although in vitro alternatives are now available, and collection of sufficient numbers of specific B cells, as well as the lack of satisfactory fusion partners, restricts their application. An approach which is under extensive investigation, is to combine the low immunogenicity of human antibodies with the antigen specificity of mouse antibodies. This may be achieved either by producing chimeric antibodies, in which only the variable (V) domains are of murine origin, or by engineering 'humanised' antibodies by recombinant DNA technology, which are entirely human except for the complementarity determining regions (CDRs) of the antigen binding site, which are defined by the gene sequences provided by the immunised mouse79 82 (Fig 7).

The problem of poor tumour localisation is aggravated by the limited penetration across blood-tissue barriers and into solid tumour masses. This problem may be addressed by the use of the antibody fragments, monomeric Fab or dimeric F(ab')2. Not only are these fragments able to penetrate better in circumstances where molecular mass restricts tumour access, but they are also cleared more rapidly from the circulation, enhancing tumour/blood ratios, and do not interact with Fc receptors.79 A recent development is the production of recombinant engineered Fv antibody fragments, which are the smallest units retaining antigen-specific binding capability.51

Another possible approach is to improve penetration of reagents into tumours by modulating tissue barriers themselves. Increased blood flow can be induced in tumours by low doses of external radiation, by injection of complement fixing anti-tumour monoclonal antibodies, or by systemic or targeted application of cytokines.83 Accessibility to the intercellular space is influenced by a number of factors, including tight junctions formed by cell-cell interactions, and the presence of, and cellular adhesion to, basement membrane components. Cellular interactions are controlled chiefly by the expression of adhesion molecules, such as neural cell adhesion molecules (NCAMs) in retinoblastoma, and basement membranes interact via cell surface integrins. Access to intercellular spaces may be improved by blocking the activity of such molecules, utilising inhibitors or specific markers of adhesion molecules, such as the anti-NCAM monoclonal antibodies UJ133A, 5.1H11, A2BS,52 53 and ERIC-1.52 53 Blocking of cellular adhesion may significantly increase metastatic potential of a tumour, therefore further investigation is needed before selecting appropriate reagents for therapeutic use.

An alternative to the use of monoclonal antibodies in specific delivery of therapeutic reagents, is to utilise conjugates of growth factors, hormone analogues, or integrin recognition motifs to target functional cell surface receptors. Many cancers originate through aberrant overexpression of growth factor receptors of the protein kinase family, due to proto-oncogene amplification, or the loss of control functions. Such possible oncogene associated targets include receptors for epidermal growth factor (oncogenes erb B, c-neu), colony stimulating factor (oncogene c-fms), stem cell factor (oncogene c-kit), and insulin (oncogene v-ros).85 86 In addition, many cancers conserve or overexpress normal tissue hormone receptors – for instance, malignant melanoma expression of melancyte stimulating hormone receptor. Targeting of receptors overexpressed in tumours may allow therapeutic delivery while minimising effects on development in normal tissues. The metastatic potential of malignant
cells is dependent to a large extent upon particular cell-cell and cell-matrix interactions, and therefore cell adhesion molecules and integrins may present suitable targets for localisation using their native ligands or specific recognition motifs. It is unlikely that such targets would alone provide adequate specificity, but may be utilised in combination for BET, or used in compartmentalised administrations.

Summary
Monoclonal antibodies have had mixed fortunes since coming to the attention of the research and medical communities; disappointment at their failure to live up to early expectations has often obscured their real value. Understanding, and in some cases overcoming, their limitations has prompted a revival in interest based on their realistic potential.

Regulation of malignant characteristics, such as proliferation and dissemination, is a highly complex process involving interaction between growth factors and membrane bound receptors, cellular and matrix interactions, and enzyme mediated remodelling of the interstitial environment in favour of growth and invasion. There is likely to be increasing interest in immunohistochemical and western blot analyses of specific markers of malignancy, leading to greater understanding of tumour progression and metastasis, and antibody interactions may even provide means of modulating these processes. For example, we are currently engaged in a western blot evaluation of NCAM expression in retinoblastoma, and results indicate a link between tumour expression and dissemination, is therefore, that some of the prospective therapies, aimed at controlling dissemination, is a recessive cancer gene. Science 1983; 219: 793–5.


Progress in the therapeutic uses of monoclonal antibodies in retinoblastoma depend to a large extent on advances made in treating other malignancies, as it is only when clear benefits are demonstrable, in terms of patient survival and morbidity, that current low risk strategies will be abandoned. It is likely, therefore, that some of the prospective therapies, aimed at overcoming the limitations of inadequate specificity, inappropriate toxicity, and poor reagent localisation shall in time be applied to retinoblastoma.

Although the potential for tumour spread leads to prophylactic use of enucleation in developed countries, metastatic retinoblastoma is still regarded as a Third World problem. For this reason potential therapy aimed at controlling disseminated disease should be both inexpensive and readily portable for access to outlying regions. Providing cold storage facilities are available, monoclonal antibody conjugates are eminently portable; nevertheless, they are also extremely expensive to produce, limiting their use in circumstances in which there are great demands on meagre health care budgets. It is very important, therefore, to look into cheap and efficient new methods of production, such as prokaryote expression systems, in order to broaden their application in both the laboratory and the clinic. Furthermore, reagents and methodologies should be standardised so as to minimise requirement for expensive specialised equipment or training of personnel.

J F TARLTON
D L EASTY
University of Bristol Department of Ophthalmology,
Bristol Eye Hospital,
Lower Maudlin Street,
Bristol BS1 2LL


20. Progress in the therapeutic uses of monoclonal antibodies in retinoblastoma depend to a large extent on advances made in treating other malignancies, as it is only when clear benefits are demonstrable, in terms of patient survival and morbidity, that current low risk strategies will be abandoned. It is likely, therefore, that some of the prospective therapies, aimed at overcoming the limitations of inadequate specificity, inappropriate toxicity, and poor reagent localisation shall in time be applied to retinoblastoma.

21. Although the potential for tumour spread leads to prophylactic use of enucleation in developed countries, metastatic retinoblastoma is still regarded as a Third World problem. For this reason potential therapy aimed at controlling disseminated disease should be both inexpensive and readily portable for access to outlying regions. Providing cold storage facilities are available, monoclonal antibody conjugates are eminently portable; nevertheless, they are also extremely expensive to produce, limiting their use in circumstances in which there are great demands on meagre health care budgets. It is very important, therefore, to look into cheap and efficient new methods of production, such as prokaryote expression systems, in order to broaden their application in both the laboratory and the clinic. Furthermore, reagents and methodologies should be standardised so as to minimise requirement for expensive specialised equipment or training of personnel.


87 Connors TA. Has chemotherapy anywhere to go? Cancer Surv 1989; 8:693–705.


Applications of monoclonal antibodies in the investigation, diagnosis, and treatment of retinoblastoma.
J F Tarlton and D L Easty

doi: 10.1136/bjo.77.12.805

Updated information and services can be found at:
http://bjo.bmj.com/content/77/12/805.citation

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/